Nanobodies®: The "hot" new research tool.
We will make Nanobodies® for you.
Single domain antibodies (nanobodies) are increasingly becoming popular as reagents for biomedical research, for use as therapeutics, and as reagents for diagnostics. The number of publications citing antibodies is increasing each year with over 2,000 publications cited in PubMed to date. This is due, in large part, to their small size, stability, high affinity, high specificity, ease of manipulation, and ease of production.
Through resources provided by the National Institute of General Medical Sciences, our University based Protein Core is producing single domain antibodies in alpacas on a fee for service structure. Our facility immunizes alpacas with your protein of interest, amplifies the produced pool of nanobody cDNAs by PCR and generates a phagemid library, which is then screened by panning against your protein. Positive clones are sequenced, with nanobodies to your target confirmed by ELISA. The nanobodies to your protein are produced and purified from E. coli with 1 mg of purified nanobody, the nanobody clone, as its sequence as deliverables. To date we have successfully generated more than 75 nanobodies. These nanobodies are for research purposes.
In many cases our core can produce your protein for nanobody production by expressing it in E. coli, insect cells, or mammalian cells and purifying it.
The next round of nanobody production will start in early September, 2021. The cost to produce a nanobody is $9,000. To produce a nanobody to your protein we need ~1.5 mg of purified protein in PBS or HBS at a concentration of 1 mg/ml or higher. We typically deliver your nanobody within ~4 – 6 months. Usually we identify more than one nanobody against a particular protein which can be purchased for a nominal cost. A range of derivatives and conjugates are also available.
To request a nanobody produced to your protein please fill out and return this request form:Nanobody Production Request Form
or contact Lou Hersh at email@example.com or 859-536-0034.
The Fall nanobody production cycle will start in early November of 2021. Your purified protein will be due in late October, a date has not been set as of this time. Please note that we cannot inject GST or MBP fusions, so if present these fusion partners need to be removed prior to sending your protein. In addition usually do not accept proteins in detergents.
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Huo et al. Nat. Struct. Biol. 2020 Sep;27(9):846-854.
Immunization of Alpacas (Lama Pacos) with Protein Antigens and Production of Antigen-specific Single-Domain Antibodies. K. Martin Chow, Sidney W. Whiteheart, Jeffrey R. Smiley, Savita Sharma, Kathy Boaz, Meggie J. Coleman, Alvina Maynard, Louis B. Hersh, Craig W. Vander Kooi. J. Vis Exp 2019 Jan 26;(14
Nanobody approval gives domain antibodies a boost. Morrison C. Nat Rev Drug Discov. 2019 Jul;18 (7) : 485-487
Exploiting Nanobodies' Singular Traits. Ingram JR, Schmidt FI, Ploegh HL. Annu Rev Immunol. 2018 Feb 28.
Reporter-nanobody fusions (RANbodies) as versatile, small, sensitive immunohistochemical reagents. Yamagata M, Sanes JR. Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2126-2131.
Editorial: Single-Domain Antibodies-Biology, Engineering and Emerging Applications. Henry KA, MacKenzie CR. Front Immunol. 2018 Jan 23;9:41.
Nanobodies as novel agents for cancer therapy. Revets H, De Baetselier P, Muyldermans S. Expert Opin Biol Ther. 2005 Jan;5(1):111-24. Review
Nanobodies and their potential applications. Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S. Nanomedicine (Lond). 2013 Jun;8(6):1013-26.